Abstract
Purpose
Palmar hyperhidrosis (PH) is a common illness that significantly impacts Quality of Life (QOL). Oxybutynin offers excellent short-term results, but long-term follow-up results are limited. We evaluated its effectiveness in a large group of patients who did not have surgery and who had at least 6 months of follow-up.
Methods
Between September 2007 and September 2013, 570 consecutive patients were enrolled in our institutional protocol regarding the “pharmacological-first” treatment of primary PH with oxybutynin. Fifty-nine were lost to follow-up, and the data were available for 511 patients treated for at least 6 weeks. Data recorded at the start of the protocol, 6 weeks after beginning treatment, and during patients’ final visits were analyzed.
Results
112 patients (21.9 %) did not improve and were referred for surgery (sympathectomy). Eight (1.56 %) developed significant side effects (e.g., dry mouth) and discontinued therapy. Thirty (5.9 %) preferred surgery over pharmacological treatment. 111 have not yet received treatment for 6 months. The 246 patients with more than 6 months of follow-up (median 16 months, range 6–72) were analyzed, as follows: 90.2 % experienced moderate or great improvement in their PH; 90.34 % experienced improvement at other sites of hyperhidrosis following a median of 16 months.
Conclusion
Among patients with good initial responses to oxybutynin, more than 90 % experienced moderate or great improvement in their palmar sweating, as well as in their hyperhidrosis in other sites, after 6 months. The results were particularly favorable in those patients with BMI <25 kg/m2, and in those who noted an improved QOL after 6 weeks.
Similar content being viewed by others
Abbreviations
- BMI:
-
Body mass index
- CH:
-
Compensatory hyperhidrosis
- PH:
-
Palmar hyperhidrosis
- QOL:
-
Quality of life
- VATS:
-
Video assisted thoracic sympathectomy
References
Cerfolio RJ, de Campos JRM, Bryant AS et al (2011) The society of thoracic surgeons expert consensus for the surgical treatment of hyperhidrosis. Ann Thorac Surg 91:1642–1648. doi:10.1016/j.athoracsur.2011.01.105
Strutton DR, Kowalski JW, Pharm D et al (2004) US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 51:241–248. doi:10.1016/j.jaad.2003.12.040
Lear W, Kessler E, Solish N, Glaser DA (2007) An epidemiological study of hyperhidrosis. Dermatol Surg 33:S69–S75. doi:10.1111/j.1524-4725.2006.32334.x
Walling HW (2009) Primary hyperhidrosis increases the risk of cutaneous infection: a case–control study of 387 patients. J Am Dermatol 61:242–246. doi:10.1016/j.jaad.2009.02.038
Wolosker N, de Campos JRM, Kauffman P, Puech-Leão P (2012) A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar andaxillary hyperhidrosis. J Vasc Surg 55:1696–1700. doi:10.1016/j.jvs.2011.12.039
Lakraj A-A, Moghimi N, Jabbari B (2013) Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins 5:821–840. doi:10.3390/toxins5040821
Milanez Ribas, de Campos J, Kauffman P, Wolosker N et al (2006) Axillary hyperhidrosis: T3/T4 versus T4 thoracic sympathectomy in a series of 276 cases. J Laparoendosc Adv Surg Tech A 16:598–603. doi:10.1089/lap.2006.16.598
Chwajol M, Barrenechea IJ, Chakraborty S et al (2009) Impact of compensatory hyperhidrosis on patient satisfaction after endoscopic thoracic sympathectomy. Neurosurgery 64:511–518. doi:10.1227/01.NEU.0000339128.13935.0E discussion 518
de Moura Júnior NB, das-Neves-Pereira JC, de Oliveira FRG et al (2013) Expression of acetylcholine and its receptor in human sympathetic ganglia in primary hyperhidrosis. Ann Thorac Surg 95:465–470. doi:10.1016/j.athoracsur.2012.10.068
LeWitt P (1988) Hyperhidrosis and hypothermia responsive to oxybutynin. Neurology 38:506–507
Mijnhout GS, Kloosterman H, Simsek S et al (2006) Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med 64:326–328
Tupker RA, Harmsze AM, Deneer VHM (2006) Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol 142:1065–1066. doi:10.1001/archderm.142.8.1065
Wolosker N, de Campos JRM, Kauffman P et al (2013) Use of oxybutynin for treating plantar hyperhidrosis. Int J Dermatol 52:620–623. doi:10.1111/j.1365-4632.2012.05746.x
Wolosker N, de Campos JRM, Kauffman P et al (2011) The use of oxybutynin for treating axillary hyperhidrosis. Ann Vasc Surg 25:1057–1062. doi:10.1016/j.avsg.2011.06.007
Wolosker N, de Campos JRM, Kauffman P et al (2011) The use of oxybutynin for treating facial hyperhidrosis. An bras de dermatol 86:451–456
Try C, Messikh R, Elkhyat A et al (2012) Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis. Rev méd de Liège 67:520–526
Wolosker N, Campos JR, Kauffman P et al (2011) An alternative to treat palmar hyperhidrosis: use of oxybutynin. Clin Auton Res 21:389–393. doi:10.1007/s10286-011-0128-4
Wolosker N, Schvartsman C, Krutman M, et al. (2013) Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. Pediatr Dermatol n/a–n/a. doi: 10.1111/pde.12142
de Campos JRM, Kauffman P, de Werebe E C et al (2003) Quality of life, before and after thoracic sympathectomy: report on 378 operated patients. Ann Thorac Surg 76:886–891
Arisco AM, Brantly EK, Kraus SR (2009) Oxybutynin extended release for the management of overactive bladder: a clinical review. Drug Des Dev Ther 3:151–161
Wolosker N, Munia MAS, Kauffman P et al (2010) Is gender a predictive factor for satisfaction among patients undergoing sympathectomy to treat palmar hyperhidrosis? Clinics (São Paulo, Brazil) 65:583–586. doi:10.1590/S1807-59322010000600004
Wolosker N, Krutman M, Campdell TPDA et al (2012) Oxybutynin treatment for hyperhidrosis: a comparative analysis between genders. Einstein (São Paulo, Brazil) 10:405–408
Vorkamp T, Foo FJ, Khan S et al (2010) Hyperhidrosis: evolving concepts and a comprehensive review. Surgeon 8:287–292. doi:10.1016/j.surge.2010.06.002
de Campos JRM, Wolosker N, Munia MAS et al (2011) Is age group a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis? J vasc bras 10:284–288
Ishy A, de Campos JRM, Wolosker N et al (2011) Objective evaluation of patients with palmar hyperhidrosis submitted to two levels of sympathectomy: T3 and T4. Interact CardioVasc Thorac Surg 12:545–548. doi:10.1510/icvts.2010.252015
de Campos JRM, Wolosker N, Takeda FR et al (2005) The body mass index and level of resection: predictive factors for compensatory sweating after sympathectomy. Clin Auton Res 15:116–120. doi:10.1007/s10286-005-0259-6
de Andrade Filho LO, Kuzniec S, Wolosker N et al (2013) Technical difficulties and complications of sympathectomy in the treatment of hyperhidrosis: an analysis of 1731 cases. Ann Vasc Surg 27:447–453. doi:10.1016/j.avsg.2012.05.026
Smidfelt K, Drott C (2011) Late results of endoscopic thoracic sympathectomy for hyperhidrosis and facial blushing. Br J Surg 98:1719–1724. doi:10.1002/bjs.7682
Acknowledgement
No financial assistance was received in support of the study.
Conflict of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wolosker, N., Teivelis, M.P., Krutman, M. et al. Long-term results of oxybutynin treatment for palmar hyperhidrosis. Clin Auton Res 24, 297–303 (2014). https://doi.org/10.1007/s10286-014-0264-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10286-014-0264-8